Date: 2014-10-08
Type of information: Collaboration agreement
Compound:
Company: Cardio3 BioSciences (Belgium) Mayo Clinic (USA - MN)
Therapeutic area: Regenerative medicine - Cardiovascular diseases
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On October 8, 2014, Cardio3 BioSciences, a leader in the discovery, development and commercialization of regenerative, protective and reconstructive therapies, announced the signing of a preferred access agreement with Mayo Clinic. Under this agreement, Mayo grants Cardio3 BioSciences preferred access to technologies developed in the Mayo Clinic Center for Regenerative Medicine, as well as select other Mayo technologies. This agreement is an expansion of a long-standing collaboration, which led to the development of C-Cure®; Cardio3 BioSciences’ product candidate now in advanced clinical trial testing (Phase III); an innovative cell therapy based on the discovery of the cardiopoiesis platform by the team of Andre Terzic, M.D., Ph.D. at Mayo Clinic. Cardio3 BioSciences identified cellular therapies as the strategic technological pillar of the Company and is looking to further extend its portfolio in this specific area. Building on its core competences and unique expertise in cellular therapies and cardiovascular diseases developed with C-Cure®, now in Phase III trial, Cardio3 BioSciences’ access to Mayo Clinic Center for Regenerative Medicine technologies is an extra asset to further strengthen the Company’s long term plan to bring the best innovative therapeutic response to unmet medical needs. With this agreement, Mayo Clinic and Cardio3 BioSciences’ unique expertise and competences will come together to accelerate innovative medical advancements to benefit patients. Mayo Clinic will significantly expand its ability to address unmet needs and Cardio3 BioSciences gains access to a broad portfolio in multiple areas such as cardiology, oncology or others, enabling the company to advance regenerative medicine’s potential. Mayo Clinic has a financial interest in Cardio3 Biosciences.
Financial terms:
Latest news:
